Table 1. T-cell lymphoma. Mexican Population

 No %

Peripheral T-cell lymphoma ,not otherwise specified 1084 28

Angioimmunoblastic ,T-cell lymphoma 199 5

Anaplastic large cell lymphoma, ALK + 587 15

Anaplastic large cell lymphoma, ALK - 279 17

Nasal NK/T-cell lymphoma 1524 40

Adult T-cell leukemia lymphoma 25 <1

Enterophaty ,T-cell lymphoma 29 <1

Subcutaneous panniculitis ,like 35 <1

Hepato-splenic 60 <1

Table 2, Nasal. NK/T-cell lymphoma. Mexican population.

 No (% )

 Stage I-II Stage III-IV

Number 1129 (74) 395 (25)

Age (years): median 50.1 46.8

 Range 22-64 27-60

Male 601 (53) 198 (48)

International Prognostic Index

 Low-Low-intermediate 989 (87) 149 (37)

 High-intermediate/High 140 (12) 246 (62)

Performance status (ECOG)

 < 2 1004 (88) 188 (47)

 > 2 125 (11) 207 (52)

Bulky disease ( nasal site, cm)

 > 10 301 (21) 67 (16)

Bone Marrow infiltration 0 127 (36)

Korean Prognostic Classification

 Group 0 608 (53) 26 ( 6)

 Group 1 414 (36) 84 (21)

 Group 2 89 ( 8) 110 (27)

 Group >3 8 (0.7) 175 (44)

Table 3. Outcome from Nasal NK/T-cell lymphoma in Mexican population

 %

 Stage I-II Stage III-IV

Complete response 91 80

Progression-free survival \* 91 81

Overall survival \* 86 65

Table IV. Geographic Charactetistics.

 No. Cases T-cell lymphoma Nasal NK/T-cell lymphoma

T-cell project (ref) 1314 12.2 %

 North America 5.1 %

 Europe 4.3 %

 Asia 22.4 %

T-project (ref) 737

 USA 9.0 %

 Europe 6.0 %

 South-America 13 %

 Middle/ Far East 31 %

 Countries 317

 Italy 5 %

 United Kingdom 4 %

 Others (Spain,Switzerland, Slovakia) 11 %

 South-America 152

 Chile 11 %

 Brazil 15 %

 Others ( Argentina, Uruguay) 15 %

Central and South America (ref) 1028 316

 Argentina 0.5 %

 Brazil 2.0 %

 Chile 2.6 %

 Guatemala 7.8 %

 Peru 4%

 Total Central and South America 2. %

 Total North America 0

Sinonasal lymphomas (ref) USA

 Nasal NK/T -cell lymphoma 23 %

 Population based register: 0.0.32/100,000 habitants